Showing 1851-1860 of 2105 results for "".
- Highlights from the 1st Spinal Cord Injury Investor Symposium: Cell Transplant Approacheshttps://practicalneurology.com/news/highlights-from-the-1st-spinal-cord-injury-investor-symposium-cell-transplant-approaches/2470286/Spinal cord injury (SCI) affects an estimated 17,500 individuals each year in the United States, and less than 1% of those with SCI will experience complete neurologic recovery upon hospital discharge. Rehabilitation, assistive devices, medications, and surgery only provide benef
- Highlights from the 1st Spinal Cord Injury Investor Symposium: The 3-Pillar Research Strategy of the Christopher & Dane Reeve Foundationhttps://practicalneurology.com/news/highlights-from-the-1st-spinal-cord-injury-investor-symposium-the-3-pillar-research-strategy-of-the-christopher-dane-reeve-foundation/2470284/Spinal cord injury (SCI) affects an estimated 17,500 individuals each year in the United States, and less than 1% of those with SCI will experience complete neurologic recovery upon hospital discharge. Rehabilitation, assistive devices, medications, and surgery only provide benef
- Encouraging Results for Investigational Cellular Therapy for Parkinson Diseasehttps://practicalneurology.com/news/encouraging-results-for-investigational-cellular-therapy-for-parkinson-disease/2470281/Results of a phase 1 study (NCT04802733) presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders revealed positive safety and tolerability outcomes through year 1 for bemdaneprocel (BRT-DA0l; BlueRock Therapeutics, Cambridge, MA) in patients with Parkinson
- Comparison of Levodopa vs Dopamine Agonists vs MOA-Bs in Patients with Early PDhttps://practicalneurology.com/news/comparison-of-levodopa-vs-dopamine-agonists-vs-moa-bs-in-patients-with-early-pd/2470279/Final results from the 15-year PD MED EARLY study demonstrated improved quality of life (QoL) scores for patients with early Parkinson disease (PD) initially treated with levodopa (LD) compared with LD-sparing therapies (dopamine agonists [DA] and inhibitors of type B monoamine oxidase [MOA-B]).
- FDA Clears Intranasal Foralumab for Clinical Investigation as a Potential Treatment for Alzheimer Diseasehttps://practicalneurology.com/news/fda-clears-intranasal-foralumab-for-clinical-investigation-as-a-potential-treatment-for-alzheimer-disease/2470269/Tiziana Life Sciences’ (New York, NY) investigational new drug (IND) application for intranasal foralumab has been cleared by the Food and Drug Administration (FDA), authorizing further investigations into the agent&r
- Subcutaneous Lecanemab Shown to Have Similar Efficacy to IV Lecanemab and May Reduce ARIA-Ehttps://practicalneurology.com/news/subcutaneous-lecanemab-shown-to-have-similar-efficacy-to-iv-lecanemab-and-may-reduce-aria-e/2470249/Subcutaneous injection of lecanemab (Eisai, Tokyo, Japan; Biogen, Cambridge, MA) using a vial or autoinjector yielded comparable average steady-state concentrations (Css) to intravenous (IV) administration o
- LUCIDITY Clinical Trial Demonstrates Reduction of Plasma Biomarker Neurofilament Light Chain in Alzheimer Disease Participantshttps://practicalneurology.com/news/lucidity-clinical-trial-demonstrates-reduction-of-plasma-biomarker-neurofilament-light-chain-in-alzheimer-disease-participants/2470247/Results from the LUCIDITY clinical trial (NCT03446001) measuring the efficacy of hydromethylthionine mesylate (HMTM; TauRx, Singapore, Singapore) treatment for individuals with mild to moderate Alz
- Habitually Taking Daytime Naps Associated with Larger Total Brain Volumehttps://practicalneurology.com/news/habitually-taking-daytime-naps-associated-with-larger-total-brain-volume/2470229/According to research published in Sleep Health, people who habitually took daytime naps had brains that were larger by a volume equivalent to 2.6 to 6.5 years of aging compared to people who didn’t nap. The fi
- Study Evaluates Stigma of High-Frequency Headache/Migraine with Acute Medication Overdose as a Factor of Age, Gender, Employment Status, and Race/Ethnicityhttps://practicalneurology.com/news/study-evaluates-stigma-of-high-frequency-headachemigraine-with-acute-medication-overdose-as-a-factor-of-age-gender-employment-status-and-raceethnicity/2470213/Stigma associated with high-frequency headache/migraine with acute medication overdose (HFM+AMO) is more prevalent in employed, non-Hispanic Black male patients aged 18-49 years, according to a new study presented at the 65
- FDA to Hold Advisory Committee Meeting to Discuss Potential Stem Cell Therapy for ALShttps://practicalneurology.com/news/fda-to-hold-advisory-committee-meeting-to-discuss-potential-stem-cell-therapy-for-als/2470210/BrainStorm Cell Therapeutics Inc (New York, NY) announced that the Food and Drug Administration (FDA) will hold a meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (AdCOM) on September 27, 2023, to consi